Option Therapeutics

Option Therapeutics

Option Therapeutics was formed to develop a pharmaceutical intervention for acute spinal cord injury, focusing on intermittent hypoxia — a treatment protocol involving controlled, brief periods of low oxygen to stimulate neural plasticity. The company designed its lead candidate as a small-molecule prodrug that mimicked the molecular benefits of intermittent hypoxia, aiming to improve respiratory function in patients with cervical spinal cord injuries. The science drew on decades of academic research into respiratory neuroplasticity and targeted a patient population with no approved pharmacological treatment. The firm operated as an early-stage biotech, attempting to bridge the gap between academic discovery and a regulatory pathway that remained largely unvalidated by any approved drug. The company's strategy centered on a single-asset pipeline calibrated for orphan and expedited regulatory designations. Its lead candidate targeted acute intermittent hypoxia pathways, with a Phase 2 clinical trial designed to measure respiratory muscle function in individuals with chronic tetraplegia. The firm sought to differentiate itself by running a study in a patient population that large pharmaceutical companies had largely ignored for drug development, where the primary endpoint was a functional improvement rather than a biomarker. The clinical program was supported by grants from the National Institutes of Health and conducted across multiple US spinal cord injury centers. The company's scientific founders included researchers from the University of Florida and the Malcom Randall VA Medical Center who had pioneered the foundational work on adenosine receptor modulation and respiratory plasticity. The company maintained a lean operational structure typical of clinical-stage biotechs, with a small team focused on clinical operations, regulatory affairs, and intellectual property management. In December 2021 the company reported positive Phase 2a clinical data showing that its lead candidate, administered orally prior to intermittent hypoxia sessions, significantly enhanced minute ventilation during breathing trials compared to placebo, meeting its primary endpoint. Financial backers and strategic partners were not publicly disclosed in detail, though the company's operations were sustained through a combination of federal research funding and private investment. Its intellectual property estate centered on formulation patents for adenosine A2A receptor antagonists used in conjunction with hypoxia protocols. The structural differentiator for Option Therapeutics lay in its mechanism-first approach to a clinically neglected endpoint: respiratory independence after spinal cord injury. While most central nervous system drug developers focused on neuroprotection or remyelination, the company targeted the respiratory motor system's capacity for plasticity — a functional domain that directly affects morbidity, mortality, and quality of life. This placed the company at the intersection of orphan disease drug development and physiological rehabilitation science, a narrow niche with high regulatory risk but a clearly defined patient need. As of mid-2026, no further public updates on the company's clinical program or corporate status are available, suggesting the company may have ceased operations or been acquired without public disclosure.